CS-3150 + Moxifloxacin + Placebo matching moxifloxacin tablet + Placebo matching CS-3150

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypertension

Conditions

Hypertension, Mineralocorticoid Receptor Antagonist

Trial Timeline

Nov 19, 2015 → Dec 23, 2015

NCT ID

NCT04019652

About CS-3150 + Moxifloxacin + Placebo matching moxifloxacin tablet + Placebo matching CS-3150

CS-3150 + Moxifloxacin + Placebo matching moxifloxacin tablet + Placebo matching CS-3150 is a phase 1 stage product being developed by Daiichi Sankyo for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT04019652. Target conditions include Hypertension, Mineralocorticoid Receptor Antagonist.

What happened to similar drugs?

20 of 20 similar drugs in Hypertension were approved

Approved (20) Terminated (1) Active (0)

✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved

✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved

✅Amlodipine + ValsartanYuhanApproved

✅Duowell® + TelmisartanYuhanApproved

✅Olmesartan medoxomil + Losartan potassium + AtenololDaiichi SankyoApproved

✅olmesartan medoxomil + hydrochlorothiazide, if necessary + PlaceboDaiichi SankyoApproved

✅olmesartan medoxomil and a CCB + olmesartan medoxomil and a diureticDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04019652	Phase 1	Completed	Nov 19, 2015	Dec 23, 2015	Hypertension

Competing Products

20 competing products in Hypertension

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	32
tadalafil + tadalafil	Eli Lilly	Phase 3	40
CS1 Administration	Cereno Scientific	Phase 2	29
CS1	Cereno Scientific	Pre-clinical	24
TX000045- Dose A + TX000045- Dose B + Placebo	Tectonic Therapeutic	Phase 2	36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	25
Tirzepatide + Tirzepatide Placebo	Eli Lilly	Approved	50
L04RD1 + L04TD3	Celltrion	Phase 1	29
Azilsartan Medoxomil	Celltrion	Pre-clinical	26
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mg	Celltrion	Phase 3	40
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	39
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg	Yuhan	Approved	47
Telmisartan + Amlodipine + Chlorthalidone	Yuhan	Phase 1	29
Temisartan/Amlodipine+Rosuvastatin + YHP1604	Yuhan	Phase 1	29
Temisartan+Amlodipine+Rosuvastatin (Combination drug) + Temisartan+Amlodipine + Temisartan+Rosuvastatin	Yuhan	Phase 3	40
Amlodipine + Valsartan	Yuhan	Approved	43
Duowell® + Telmisartan	Yuhan	Approved	43
YHP1701 + YHR1703 + YHR1704	Yuhan	Phase 3	40
YH22189 + Twynsta 80/10mg + Crestor 20mg	Yuhan	Phase 1	21
OM 40 + OM/HCTZ 40/12.5	Daiichi Sankyo	Phase 3	40